RET and non-small cell lung carcinoma: Despite the clarity in guideline recommendations mandating certain biomarker testing in NSCLC (1, 2, 22, 23), and the definitive patient benefit associated with targeted agents as exemplified in the example of RET inhibitors, testing for these drivers may vary by geography and by institution.